Orion Corp
KRX:271560

Watchlist Manager
Orion Corp Logo
Orion Corp
KRX:271560
Watchlist
Price: 104 800 KRW -0.47% Market Closed
Market Cap: 4.1T KRW
Have any thoughts about
Orion Corp?
Write Note

Orion Corp
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Orion Corp
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Orion Corp
KRX:271560
Long-Term Debt
â‚©14.3B
CAGR 3-Years
-53%
CAGR 5-Years
-42%
CAGR 10-Years
N/A
CJ CheilJedang Corp
KRX:097950
Long-Term Debt
â‚©6T
CAGR 3-Years
-1%
CAGR 5-Years
-1%
CAGR 10-Years
5%
Ottogi Corp
KRX:007310
Long-Term Debt
â‚©269B
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
11%
S
Samyang Foods Co Ltd
KRX:003230
Long-Term Debt
â‚©168.3B
CAGR 3-Years
34%
CAGR 5-Years
87%
CAGR 10-Years
105%
Dongwon Industries Co Ltd
KRX:006040
Long-Term Debt
â‚©1.4T
CAGR 3-Years
24%
CAGR 5-Years
7%
CAGR 10-Years
19%
Nongshim Co Ltd
KRX:004370
Long-Term Debt
â‚©29.4B
CAGR 3-Years
-35%
CAGR 5-Years
-17%
CAGR 10-Years
22%
No Stocks Found

Orion Corp
Glance View

Market Cap
4.1T KRW
Industry
Food Products

Perched within the competitive landscape of pharmaceuticals, Orion Corporation has steadily carved its niche since its inception in Finland in 1917. Starting as a small-scale factory operation, Orion has evolved into a pivotal player in the healthcare sector, blending traditional expertise with cutting-edge innovations. The company's core operations pivot around the development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). This dual focus allows Orion not only to reach a diverse market but also ensures a consistent revenue stream, supplemented by its strategic interest in self-care products. The company thrives on its robust research and development arm, constantly seeking innovations in therapeutic areas like central nervous system disorders, oncology, and respiratory diseases. Orion's financial engine hums efficiently through its vertically integrated business model. By managing most of the value chain internally—from drug discovery to production and distribution—Orion secures cost advantages and quality control, translating into a competitive edge in global markets. While Europe remains Orion's stronghold, it strategically seeks growth in regional markets, leveraging partnerships and alliances with international pharmaceutical giants to expand its footprint. This strategy not only augments its own pipeline with licensed products but also fortifies its market position, making it a sustainable player in an industry driven by constant change and regulated rigorously. The corporation's revenue streams thus embody a careful balance of organic product development and strategic collaborations, evidencing a business acumen grounded in long-term vision.

Intrinsic Value
153 695.88 KRW
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Orion Corp's Long-Term Debt?
Long-Term Debt
14.3B KRW

Based on the financial report for Sep 30, 2024, Orion Corp's Long-Term Debt amounts to 14.3B KRW.

What is Orion Corp's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
-42%

Over the last year, the Long-Term Debt growth was -12%. The average annual Long-Term Debt growth rates for Orion Corp have been -53% over the past three years , -42% over the past five years .

Back to Top